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Abstract
Neuropeptide Y (NPY) is a strong candidate gene for coronary artery disease (CAD). We have previously identified genetic
linkage to familial CAD in the genomic region of NPY. We performed follow-up genetic, biostatistical, and functional analysis
of NPY in early-onset CAD. In familial CAD (GENECARD, N=420 families), we found increased microsatellite linkage to
chromosome 7p14 (OSA LOD=4.2, p=0.004) in 97 earliest age-of-onset families. Tagged NPY SNPs demonstrated linkage to
CAD of a 6-SNP block (LOD=1.58–2.72), family-based association of this block with CAD (p=0.02), and stronger linkage to
CAD in the earliest age-of-onset families. Association of this 6-SNP block with CAD was validated in: (a) 556 non-familial
early-onset CAD cases and 256 controls (OR 1.46–1.65, p=0.01–0.05), showing stronger association in youngest cases (OR
1.84–2.20, p=0.0004–0.09); and (b) GENECARD probands versus non-familial controls (OR 1.79–2.06, p=0.003–0.02). A
promoter SNP (rs16147) within this 6-SNP block was associated with higher plasma NPY levels (p=0.04). To assess a causal
role of NPY in atherosclerosis, we applied the NPY1-receptor–antagonist BIBP-3226 adventitially to endothelium-denuded
carotid arteries of apolipoprotein E-deficient mice; treatment reduced atherosclerotic neointimal area by 50% (p=0.03).
Thus, NPY variants associate with atherosclerosis in two independent datasets (with strong age-of-onset effects) and show
allele-specific expression with NPY levels, while NPY receptor antagonism reduces atherosclerosis in mice. We conclude that
NPY contributes to atherosclerosis pathogenesis.
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Introduction
The prevalence of early-onset cardiovascular disease in
Americans (under 40 years of age) is approximately 10–15% [1]
and the hereditary nature of coronary artery disease (CAD) is well-
established [2]. The relative risk of developing CAD in a first
degree relative is 3.8 to 12.1, with higher risk correlating with
earlier age-of-onset [3]. Recent successes suggest that CAD genes
can be identified through comprehensive genetic and functional
studies [4–6]. However, the genetic architecture of CAD remains
complex and poorly understood.
To identify genetic risk factors in early-onset CAD, we
implemented a strategy combining the strengths of family-based
studies with validation by case-control association, in conjunction
with careful consideration of phenotype and functional data. In
our own GENECARD linkage study of early-onset CAD, we have
found five genomic regions of linkage with multipoint linkage odds
(LOD) scores .1.0 [7]. The neuropeptide Y gene (NPY) is located
adjacent to the peak microsatellite marker in the 7p14 peak.
Because of its proximity to the peak marker, and because NPY has
been implicated in disorders of vascular smooth muscle cell
proliferation [8,9], we sought to examine NPY further as a
candidate gene for early-onset CAD.
NPY is the most abundant peptide in the heart and brain, and is
produced by sympathetic neurons, endothelial cells [10], and
platelets [11]. NPY has diverse functions including roles in
sympathetic nerve stimulation through co-release with norepi-
nephrine; immune function [12]; regulation of food consumption
[9]; and modulation of heart rate, vasoconstriction, coronary
blood flow and ventricular function [13]. These cardiovascular
functions are primarily mediated through the NPY1 receptor
[12,14,15]. In injured rat carotid arteries, non-atherosclerotic
neointimal hyperplasia is aggravated by local delivery of NPY, and
ameliorated by treatment with NPY1 receptor antagonist [8,9]. In
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stage renal disease [16], and NPY is implicated in congestive heart
failure [17]. An NPY variant rare in most populations has been
associated in Scandinavian populations with hyperlipidemia and
carotid atherosclerosis [18,19], CAD in type 1 diabetics [20], and
MI in hypertensive patients [21]; however, the effects of this
variant on NPY expression remain obscure.
To date there have been no systematic studies of the role of the
NPY gene, or of the functional consequences of genetic variation at
this locus, in cardiovascular disease pathogenesis. In response to
the results of the genome-wide linkage analyses, the phenotypic
correlations, and the strong but limited prior published work, we
proposed to test the hypothesis that NPY variants affect
atherosclerosis through effects on NPY plasma levels. We pursued
a comprehensive gene-wide approach to correlating NPY variants
with CAD and plasma NPY levels in humans, and tested the
effects of NPY1 receptor blockade on atherosclerosis in mice.
Results
Table 1 presents baseline characteristics of the three datasets:
GENECARD (N=946 affected, 37 unaffected individuals);
CATHGEN (N=556 cases, 256 controls); and GENECARD
probands versus CATHGEN controls (N=221 cases, 256
controls). Despite GENECARD families being selected on early
age-of-onset, genetic heterogeneity manifest as differences in age-
of-onset could still be present, as observed in the discovery of the
BRCA1 breast cancer gene [22]. Hence, we performed ordered
subset analysis (OSA) to understand the effect of age-of-onset on
linkage to CAD. We found increased linkage on the chromosome
7p14 peak in a subset of 97 families with the youngest age-of-onset
(overall LOD=1.04; subset LOD=4.22; p=0.004 for increase,
Figure 1). The mean age-of-onset in these families was 37.8 years,
and they had significantly higher mean total- and LDL-cholesterol
and were more often male, compared with affected members of
the remaining 323 families. No other genomic regions showed a
correlation between linkage and age-of-onset. The NPY gene
resides within this linkage peak and is a strong biological
candidate. As a result we aimed to evaluate NPY polymorphisms,
NPY levels, and age-of-onset of CAD, along with evaluating the
role of NPY in a mouse model system.
Author Summary
Early-onset coronary artery disease (CAD) has a very strong
genetic component as evidenced by the heritable nature
of this disease. However, little is known about the actual
genes underlying disease risk. Neuropeptide Y (NPY) is an
abundant protein in humans that has been implicated in
cardiovascular disease pathophysiology, but comprehen-
sive evaluation of the gene coding for this protein has
never been pursued in cardiovascular disease. Therefore,
using gene-wide evaluation of variants within the NPY
gene in a family-based as well as a non-familial study, we
have shown that a cluster of six related NPY genetic
variants is associated with early-onset CAD risk. We then
show that one of these variants, which resides within the
promoter region of this gene, is associated with higher
NPY levels. Finally, to further support the functional role of
this gene in CAD, we find that antagonism of the primary
receptor of this gene results in marked attenuation of
atherosclerosis in a mouse model. In conclusion, these
findings demonstrate the role of the NPY gene in
cardiovascular disease risk and add important additional
information about the genetic architecture of this complex
disease.












Age 51.5 (7.1) 50.8 (6.6) 51.1 (7.9) 43.4 (8.1) 69.3 (6.5)
Age-of-onset 43.7 (5.8) 43.8 (5.7) 46.2 (6.4) 34.7 (3.3) N/A
Sex (% male) 68.0% 68.0% 79.7% 83.8% 38.7%
Race
% Caucasian 91.9% 83.1% 71.9% 68.9% 77.4%
% African- American 2.3% 7.4% 20.5% 21.9% 16.7%
Dyslipidemia 82.4% 83.7% 72.5% 81.2% 41.8%
Lipids
TC 205.6 (57.4) 216.3 (59.0) 194.2 (55.8) 201.1 (71.6) 192.5 (50.3)
TG 221.6 (166.5) 224.7 (149.5) 225.7 (263.2) 281.2 (391.8) 163.4 (140.2)
HDL 38.2 (10.7) 35.5 (9.6) 39.8 (11.8) 38.5 (9.6) 51.7 (17.7)
LDL 117.9 (45.9) 131.6 (53.0) 113.5 (43.0) 115.2 (46.3) 106.3 (34.7)
Hypertension 55.2% 60.4% 68.5% 66.2% 65.2%
Diabetes 20.9% 25.6% 31.7% 27.0% 16.4%
BMI (SD) 29.7 (5.7) 30.6 (6.3) 30.8 (6.5) 31.9 (6.5) 28.8 (7.4)
Smoking 33.2% 26.5% 68.7% 75.7% 38.3%
History of MI 63.1% 61.7% 52.2% 52.7% 0%
Family history CAD 100% 100% 54.1% 70.3% 22.3%
*Continuous variables presented as mean (SD).
doi:10.1371/journal.pgen.1000318.t001
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Twenty-four SNPs were genotyped and were in Hardy-
Weinberg equilibrium. Rs5571 was monomorphic and not
analyzed further. Consistent with microsatellite results, nine NPY
SNPs had LOD.1.0 in GENECARD, with higher LODs for
several SNPs in the subset of 97 very-young-age-of-onset OSA
families. Six of these linked SNPs also showed family-based
association with CAD by PDT in GENECARD (Table 2). These
SNPs are in varying degrees of LD (Figure 2). Association with
CAD was validated in the non-familial dataset CATHGEN for
five SNPs within the 6-SNP block; the sixth SNP (rs16147)
demonstrated borderline significance (Table 3). CATHGEN
results also validated our GENECARD findings for age-of-onset
effects, with stronger association in the youngest age-of-onset CAD
cases (,38 years of age, threshold defined by the GENECARD
OSA subset). Although the CATHGEN sample size decreased
using this age-of-onset threshold, SNPs within the 6-SNP block
remained significantly associated to CAD (Table 3), with odds
ratios higher than those obtained with the full dataset, and with
several SNPs showing greater significance than the overall cohort
(e.g., rs16119, allelic OR 2.20, p=0.0004). These very-young-age-
of-onset cases had a higher prevalence of family history of CAD
(p=0.003) and a trend for higher prevalence of dyslipidemia
(p=0.07).
All six key NPY SNPs were also associated with early-onset CAD
in the comparison of GENECARD probands with CATHGEN
controls (Table 4). Although we had adjusted for race in our
regression models, to further address the potential for population
stratification we performed analyses stratified by race. In these
analyses, the association between NPY SNPs and early-onset CAD
remained consistent and often more significant in self-reported
Caucasians (Table S1), suggesting that the results are not
confounded by population stratification from race. However,
there was no association between NPY SNPs and CAD in non-
Caucasians, most likely due to the lower power to detect such a
difference given the small sample size (N=162 CATHGEN non-
Caucasian CAD cases, 72 non-Caucasian controls). Haplotype
analysis in the CATHGEN dataset showed association of several
two-SNP haplotypes with CAD, recapitulating the LD structure of
the individual SNPs, but not providing additional information.
The haplotype most strongly associated was composed of rs5574
and rs16474 (p=0.005).
Because rs16147 is a promoter SNP with established effects on
expression of the gene [23–25], and all other key NPY SNPs are in
LD with rs16147, we will focus the remainder of our results
primarily on rs16147. However, as expected, findings were
consistent across all six SNPs. As with the other five SNPs, there
was consistency of the CAD-associated allele for rs16147 (G allele)
and of its allele frequency across all datasets (CATHGEN cases
0.49; very-young CATHGEN cases 0.55; GENECARD probands
0.55; CATHGEN controls 0.43) (Table S2).
To test the possibility that associations between NPY SNPs with
CAD are mediated through traditional CAD risk factors, we
performed multivariable regression in our case-control datasets,
using hypertension, dyslipidemia, diabetes, BMI, and smoking as
covariates with NPY SNP genotype. In this analysis, the association
of rs16147 with CAD remained significant in our comparison of
GENECARD probands with CATHGEN controls (genotype OR
1.60 [95% CI 1.11–2.31], p=0.01; allele OR 2.00 [1.11–3.59],
p=0.03), suggesting that NPY genotype contributes to CAD risk
independently of traditional risk factors, at least in family-based
cohorts. In the CATHGEN cohort, however, adjusting for risk
factors attenuated association for rs16147 (genotype OR 1.15
[0.87–1.51], p=0.34; allele OR 1.24 [0.82–1.88], p=0.32), but
left the association of rs16120 with CAD intact (allele model, OR
1.54 [1.01–2.35], p=0.04). Race-stratified analyses in Caucasians
also showed attenuation of association between NPY SNPs and
early-onset CAD, although three of the SNPs remained signifi-
cantly associated (Table S1).
To understand which CAD risk factor(s) most mediate association
of NPY genotype with CAD, we performed a forward stepwise logistic
regression, first fitting a model with genotype and then adding each
risk factor. The greatest attenuation of association was caused by
dyslipidemia, with minimal additional attenuation by other variables.
Table S3 lists risk factors significant in the multivariablemodel for the
SNP remaining significant after adjustment (rs16120), demonstrating
the independent strength of effect of genotype, as well as those for
intermediate risk factors, in a full fitted model. Neither BMI nor
cholesterol levels varied significantly by NPY genotype (data not
shown). Thus, it appears that NPY SNPs may contribute to
atherosclerosis risk either independently of traditional risk factors,
especially in high-risk families, or via mechanisms that may relate to
dyslipidemia in non-familial CAD.
NPY Risk Alleles Are Associated with a Younger Age-of-
Onset
An alternate way to examine the relationship between
quantitative covariates and genetic variants is comparing means
of traits by genotype (measured genotype analysis). We performed
this analysis in CATHGEN to elucidate further the influence of
NPY variants on age-of-onset. We found that the risk allele for
rs16147 is indeed associated with a younger age-of-onset (mean
age-of-onset: 45.8 (SD 6.5) in subjects with 1 or 2 copies of risk
allele versus 47.3 (5.9) in subjects with 0 copies, p=0.03). These
results support our GENECARD findings and suggest NPY may
affect the course of atherogenesis such that atherosclerosis
manifests earlier in life.
Figure 1. Ordered subset analysis (OSA) using age-of-onset in
GENECARD, chromosome 7. We constructed a CAD linkage map
using the GENECARD microsatellite genome screen on chromosome 7.
Results are depicted for all 420 families (grey), and for the subset
generated by OSA (black), demonstrating increased LOD at the peak
microsatellite from 1.04 (420 families) to 4.22 (97 lowest age-of-onset
families, mean 37.8 years), p=0.004 for increase in LOD.
doi:10.1371/journal.pgen.1000318.g001
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To examine allele-specific effects, we assessed the relationship of
NPY variants with peripheral NPY levels in 220 subjects randomly
selected from the CATHGEN case/control dataset. We found that
rs16147 was associated with higher NPY levels for the minor (risk,
G) allele compared with the major (A) allele (46.3 vs. 41.0 pmol/L,
p=0.04, Figure 3). Concordantly, NPY levels were higher in CAD
cases compared with controls (46.8 vs. 41.1 pmol/L, p=0.02).
Antagonism of NPY Reduces Atherosclerosis
To determine whether NPY-evoked signaling contributes to
atherosclerosis, we attenuated the vascular effects of NPY [26]
with an NPY1 receptor antagonist that does not cross the blood-
brain barrier: BIBP 3226 (BIBP) [8,26,27], which has been shown
to reduce non-atherosclerotic neointimal hyperplasia in rats
[8,26]. In order to accelerate typical atherosclerosis in a focal
manner, we employed carotid endothelial denudation in apoe
2/2
mice, as reported by other groups [28,29]. With this approach, we
could apply BIBP just focally to the carotid artery in a peri-arterial
Pluronic gel. Atherosclerosis developed typically in this carotid
model, with abundant evidence of macrophage foam cells, SMC-
like cells constituting fibrous caps of complex intimal lesions, and
extracellular cholesteryl ester (Figure 4A–4C). Peri-carotid appli-
cation of Pluronic gel by itself had no effect on extent of
atherosclerosis (data not shown), and BIBP in the gel did not
engender cell toxicity, as judged by apoptosis: cleaved caspase-3
levels were 70620% higher in control than in BIBP-treated
carotids (p,0.02, Figure 4D–4E). While control specimens
demonstrated greater apoptosis than BIBP-treated specimens,
they also demonstrated 1.760.3-fold greater cell proliferation, as
judged by immunofluorescence for proliferating cell nuclear
antigen (PCNA, Figure 4F, 4G). However, while BIBP did not
affect the prevalence of macrophages, SMCs or collagen in
atherosclerotic plaques, it reduced total plaque cell number,
collagen content and plaque area by 56% (p,0.03, Figure 5).
Thus, it appears that NPY, through the NPY1 receptor and
perhaps other NPY receptors, contributes to atherogenesis.
Discussion
Our data provide the first evidence that NPY gene variants
associate with CAD in humans, particularly those with early-onset
CAD, and that NPY contributes to atherosclerosis in mice through
its NPY1 receptor. Our results supporting the role of NPY in CAD
pathogenesis emerge from multiple lines of evidence, including
linkage, family-based and case-control association studies in
multiple cohorts, as well as allele-specific differential NPY levels.
Table 2. Linkage and family-based association of NPY SNPs with CAD (GENECARD).
SNP
Overall Two-Point LOD All Families
(N=420)
LOD OSA Very Young AOO Families
(N=97) PDT Geno-PDT
Dom Rec Dom Rec P-value P-value
RS7800861 0.25 0.09 0.43 0.35 0.49 0.50
RS16148 0.38 0.25 0.45 0.31 0.10 0.25
RS16147 1.88 1.39 2.10 1.16 0.05 0.03
RS16143 0.20 0.05 0.47 0.18 0.69 0.50
RS16478 0.16 0.17 0.27 0.21 0.41 0.29
RS16142 0.24 0.08 0.19 0.11 0.41 0.29
RS16141 1.62 1.15 1.92 1.19 0.12 0.17
RS16140 0.01 0.01 0.27 0.19 0.62 0.67
RS16139 0.03 0.01 0.03 0.02 1.00 1.00
RS5572 0.89 0.46 0.24 0.31 1.00 1.00
RS9785023 1.87 1.17 2.13 1.03 0.04 0.05
RS16138 0.19 0.06 0.41 0.20 1.00 0.39
RS1468271 0.09 0.26 0.16 0.68 0.78 0.78
RS5574 2.13 1.26 2.73 1.37 0.02 0.05
RS16132 0.40 0.39 1.07 0.92 0.17 0.17
RS16131 1.42 0.86 1.09 0.68 0.08 0.08
RS16475 0.10 0.29 0.70 0.76 0.16 0.16
RS16126 0 0 0 0 1.00 1.00
RS16474 2.72 2.26 1.72 1.13 0.04 0.02
RS16473 1.91 1.62 1.56 0.94 0.08 0.18
RS16120 1.63 1.33 1.32 0.73 0.03 0.04
RS16119 1.58 1.14 1.62 0.85 0.04 0.08
RS17374047 0.07 0.28 0.18 0.16 0.74 0.57
PDT: Pedigree-Disequilibrium-Test.
SNPs with PDT p-value#0.05 in bold. SNPs listed in order of genomic location (39R59).
Dom: dominant; Rec: recessive.
doi:10.1371/journal.pgen.1000318.t002
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NPY SNPs and CAD in the very youngest age-of-onset cases, NPY
may make a particularly appealing therapeutic target for CAD
prevention in families with early-onset disease. Together with our
mouse data, our results support the following scenario by which
NPY variants promote atherosclerosis: presence of the rs16147 risk
Table 3. Association of NPY SNPs with early-onset CAD in CATHGEN, adjusted for race and sex.
SNP CATHGEN Cases CATHGEN Very-young AOO Cases
Genotype Allele Genotype Allele
OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
RS16147 1.25 (0.97–1.62) 0.08 1.33 (0.91–1.94) 0.15 1.55 (1.01–2.38) 0.05 1.84 (0.91–3.72) 0.09
RS9785023 1.27 (0.99–1.63) 0.06 1.46 (1.00–2.12) 0.05 1.59 (1.04–2.43) 0.03 1.98 (0.99–3.99) 0.06
RS5574 1.29 (1.01–1.66) 0.04 1.48 (1.04–2.12) 0.03 1.51 (0.99–2.30) 0.06 2.01 (1.03–3.92) 0.04
RS16474 1.32 (1.03–1.70) 0.03 1.57 (1.08–2.29) 0.02 1.62 (1.06–2.47) 0.03 1.93 (0.96–3.89) 0.07
RS16120 1.34 (1.05–1.73) 0.02 1.65 (1.13–2.40) 0.01 1.57 (1.03–2.40) 0.04 2.07 (1.01–4.23) 0.05
RS16119 1.32 (1.02–1.70) 0.03 1.57 (1.07–2.31) 0.02 1.59 (1.07–2.35) 0.02 2.20 (1.43–3.38) 0.0004
AOO: age of onset; OR: Odds Ratio; 95% CI: 95% Confidence Interval; p: p-value. All case groups compared with CATHGEN controls.
doi:10.1371/journal.pgen.1000318.t003
Figure 2. NPY structure, genotyped SNPs, and LD between SNPs. NPY gene structure is displayed diagrammatically (top), with exons
symbolized as cylinders, and sites of translation initiation (ATG) and termination (TGA) indicated. Genotyped SNPs are noted with arrows and color-
coded: coding-nonsynonymous (red); coding-synonymous (green); intronic (blue); mRNA-untranslated region (lavender); 59 and 39 gene-flanking
region (black). The bottom panel constitutes a LD graphic with R
2 values (n610
2) between SNPs; darker squares signify higher degrees of LD. SNPs
genotyped as part of this study are highlighted in yellow.
doi:10.1371/journal.pgen.1000318.g002
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NPY1 (and perhaps other) receptors, promotes arterial smooth
muscle cell proliferation [30], thereby promoting atherogenesis.
To our knowledge, ours is the first study to take a gene-wide
approach to NPY in cardiovascular disease. Furthermore, the NPY
variant rs16147 has never been reported for any cardiovascular
phenotypes. Because rs16147 is not in LD with upstream SNPs, it
appears that the LD block tagged by rs16147 does not extend
beyond the gene (www.hapmap.org). This inference is supported
by our own data: the upstream rs7800861 is not in LD with
rs16147 or other key SNPs.
The allele-specific effects of the NPY promoter SNP rs16147 (A/
G) on NPY expression have been documented in three previous
studies [23–25]. In accord with our work, two of these studies have
observed that the rs16147 G allele (reverse strand C allele)
increases NPY expression [23,24]. Furthermore, a putative SP1
transcription factor binding site within the rs16147 stretch of NPY
sequence is lost with the rs16147 A allele [24]; consequently, we
Table 4. Association of NPY SNPs with early-onset CAD,
GENECARD probands compared with CATHGEN controls,
adjusted for race and sex.
SNP GENECARD Probands
Genotype Allele
OR (95% CI) p-value OR (95%CI) p-value
RS16147 1.55 (1.15–2.09) 0.004 1.79 (1.12–2.88) 0.016
RS9785023 1.54 (1.15–2.06) 0.004 1.88 (1.18–3.00) 0.008
RS5574 1.57 (1.17–2.11) 0.003 1.89 (1.21–2.96) 0.005
RS16474 1.63 (1.21–2.19) 0.001 2.06 (1.28–3.31) 0.003
RS16120 1.58 (1.18–2.12) 0.002 2.02 (1.25–3.24) 0.004
RS16119 1.56 (1.15–2.11) 0.004 1.98 (1.21–3.24) 0.007
OR: Odds Ratio; 95% CI: 95% Confidence Interval.
doi:10.1371/journal.pgen.1000318.t004
Figure 3. Rs16147 is associated with higher plasma NPY levels.
NPY levels were measured in fasting plasma (N=220). Box-and-whisker
plots are presented displaying mean (+), median, and 25–75
th
interquartile range (shaded boxes), according to number of risk alleles
at rs16147. *P=0.04 for comparison of 1 or 2 vs. 0 risk alleles.
doi:10.1371/journal.pgen.1000318.g003
Figure 4. Mouse carotid atherogenesis: cellular effects of a NPY Y1 receptor antagonist. Immediately after wire-mediated endothelial
denudation, carotid arteries of apoe
2/2 mice were encased in Pluronic gel lacking (‘‘None,’’ ‘‘control’’) or containing the NPY1 receptor-selective
antagonist BIBP 3226 (‘‘BIBP’’). Carotid arteries were harvested 6 wk (A–C) or 2 wk (D–G) postoperatively, and processed as described in Methods. A,
B, Typical atherosclerosis in a representative control-treated carotid artery. Frozen sections were stained for DNA and (immunofluorescently) with IgG
specific for SMC a-actin and either the macrophage marker Mac3 (A), or an isotype negative control rat IgG (B). Green autofluorescence of the elastic
laminae can be seen in both A and B. Alternatively, frozen sections were stained for cholesteryl ester with Sudan IV and hematoxylin counterstain (C).
Scale bar=100 mm. D, E, Carotid sections were stained with IgG for cleaved caspase-3 (apoptosis marker) and counterstained for DNA; specimens
stained with non-immune rabbit IgG yielded no red immunofluorescence (not shown). Scale bar=50 mm. F, G, Carotid sections were stained with IgG
for proliferating cell nuclear antigen (PCNA), counterstained for DNA, and oriented with the lumen side upward. The closed arrow designates a single
PCNA-positive nucleus in the tunica media, representative of .20 such nuclei in the field shown; specimens stained with non-immune rabbit IgG (not
shown) yielded only elastic lamina autofluorescence, like that observed in panels F and G. IEL, internal elastic lamina, indicated by the open arrows.
Scale bar=50 mm. All images are representative of $4 independent specimens stained with each modality.
doi:10.1371/journal.pgen.1000318.g004
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contrast, Zhou et al recently studied NPY expression in post-
mortem brain and virally transformed lymphoblastoid cells and
found that the rs16147 A allele results in higher, rather than lower
expression of NPY [25]. Zhou et al. also found that haplotypes
reporting on the rs16147 A allele result in higher NPY plasma
levels [25]. However, it is important to note that Zhou et al.
collected plasma from patients under resting conditions, whereas
we collected plasma from patients under arguably stressful
conditions, immediately before they underwent coronary angiog-
raphy. Furthermore, differences in cell and tissue types examined
in these studies may underlie the discordant results obtained for
NPY expression. Given previous studies showing that NPY levels
are higher in cardiovascular disease [16,31] (findings that were
corroborated in our study), and the strong concordance of our
results showing a higher frequency of the rs16147 G allele in CAD
cases, it follows that the G allele would result in increased NPY
expression, as observed in the previous NPY studies [23,24] and in
our study. Taken together, all of these studies nevertheless imply a
functional role for rs16147.
One prior linkage scan has implicated chromosome 7p in
atherogenesis, showing modest linkage to carotid plaque (LOD
0.60–0.78, p=0.03–0.05) [32]. A recently published study has also
shown linkage on chromosome 7p15 (LOD 3.3) to pulse pressure,
a measure of central arterial stiffness and a predictor of
cardiovascular mortality [33]. None of the genomewide associa-
tion studies (GWAS) of atherosclerosis have published association
with variants on chromosome 7p. However, we reviewed
individual SNPs through the Framingham SHARe GWAS
database (dbGAP, http://www.ncbi.nlm.nih.gov/projects/gap)
and found association of several flanking NPY SNPs with
cardiovascular phenotypes (Text S1, p=0.04–0.0005). These
results provide further support for a role for NPY in human
atherosclerosis.
Although previously associated with atherosclerosis primarily in
Scandinavian subjects [18–20], the NPY SNP rs16139 was not
associated with CAD in our sample. Our inability to replicate
association for rs16139 may have resulted from the low minor
allele frequency of rs16139 in our cohorts (similar to other non-
Scandinavian populations [34]), and hence the small power of our
studies for rs16139. Alternatively, the relationship between
rs16139 and atherosclerosis in Scandinavians, which is as yet
mechanistically obscure, may not pertain to our genetically more
diverse cohorts. Concomitantly, we note that rs16147 is very
common, and despite a modest relative risk conferred, this variant
may have a higher population attributable risk in genetically
diverse cohorts. In fact, 21% of our CATHGEN subjects are
homozygous for the rs16147 risk allele. This prevalence is similar
in magnitude to that observed with the recently identified
chromosome 9p21 CAD susceptibility variant discovered through
GWAS [5].
We cannot exclude the possibility that our CATHGEN data are
affected by population stratification; however we adjusted for race
and CATHGEN subjects were recruited from only one site.
Furthermore, race-stratified analyses showed consistent, and often
more significant, association between NPY SNPs and CAD in
Caucasians, though our analyses were underpowered to assess
such relationships in non-Caucasians. Importantly, there is no
evidence of population stratification in previous GENECARD
analyses [7] and, unlike the non-familial case-control regression
analyses which are sensitive to population stratification, the family-
based association analyses are robust to population stratification.
The allele frequencies of the NPY SNPs were remarkably similar
in very-young-age-of-onset CATHGEN cases and GENECARD
probands. Consequently, these independent cohorts appear to be
genetically as well as clinically similar, in that they demonstrate a
strong genetic component to their risk profiles. These very young
individuals represent a prime target for prevention. In identifying
the association between NPY variants and atherosclerosis, our
results highlight the importance of pursuing a comprehensive
gene-wide SNP survey. The replication of our GENECARD
findings in our CATHGEN validation dataset is very consistent,
not just for the NPY gene itself but also for the association of the
individual associated alleles of each SNP, suggesting it is extremely
unlikely that results are due to chance alone. It remains to be
determined whether association between NPY and CAD is
influenced by traditional CAD risk factors, particularly dyslipide-
mia, and whether a particular constellation of risk factors along
with NPY SNPs is related to the very early-onset CAD associations
observed in both GENECARD and CATHGEN. A more
Figure 5. Reduction of atherosclerosis by antagonism of the
NPY Y1 receptor. Mice treated identically to those in Figure 4
underwent carotid harvest 6 weeks after endothelial denudation, as
described in Methods. A, Carotid sections from mice subjected to the
indicated treatment were stained with a modified connective tissue
stain (green=collagen, black=elastin, red=cytoplasm) [39]. Sections
shown are representative of 3 obtained from each of 5 mice in each
treatment group. Scale bar=100 mm. B, Computerized morphometry
was used to quantitate the indicated carotid artery dimension, as
described in Methods; the means6S.E. of 5 independent carotid arteries
from each treatment group are shown. Compared with control: p,0.03.
doi:10.1371/journal.pgen.1000318.g005
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risk factors, and CAD will require additional studies.
In our study, the correlation between SNPs in the form of LD
makes a Bonferroni correction for multiple comparisons too
conservative. Using a method that corrects for LD [35] resulted in
11 minimally redundant SNPs (corrected p,0.0047). Thus, one
SNP for our CATHGEN very-young-age-of-onset group (rs16119,
p=0.0004) and most SNPs for the GENECARD proband
comparison group would remain significant. More importantly,
we have used additional statistical and functional studies to
demonstrate that association of NPY SNPs with CAD does not
result from chance alone: the convergence of evidence from
linkage and association, as well as replication of the same SNP/
CAD association in independent cohorts. The possibility that NPY
contributes to atherosclerosis is supported by the correlation of
plasma NPY levels with NPY SNP risk alleles, and the inhibition of
murine atherosclerosis with an antagonist of the NPY1 receptor,
which mediates most cardiovascular effects of NPY [8].
In summary, NPY is a strong candidate gene for early-onset
CAD. NPY SNPs may help refine CAD risk estimates and target
therapies for young members of families with CAD.
Methods
Study Sample and Phenotype Description
The GENECARD study enrolled 920 families with early-onset
CAD (age-of-onset before 51 years for men, 56 years for women)
to perform affected-sibling-pair linkage [7]. GENECARD families
were recruited based on the presence of at least two siblings with
early-onset CAD defined by: stress testing with ischemia;
myocardial infarction (MI); coronary revascularization; or angi-
ography with $50% stenosis in one major vessel. Unaffected
family members had no clinical evidence of CAD and age .55
years for men (.60 years for women). The 420 families from the
initial linkage scan [7] are included in this report, including a
limited number of unaffected family members (N=37).
An independent non-familial validation cohort was selected
from the CATHGEN biorepository, consisting of subjects
recruited sequentially through the cardiac catheterization labora-
tories at Duke University Medical Center (Durham, NC). Fasting
whole blood and plasma samples were obtained from the femoral
artery during cardiac catheterization and frozen prior to use. CAD
cases were defined as CAD-index$32 (at least one vessel with
$95% stenosis) with age-of-onset ,56 years. CADi is a numerical
summary of angiographic data directly related to outcome [36].
Age-of-onset was defined as age at first MI, coronary revascular-
ization, or catheterization meeting CADi threshold. Controls were
defined as age-at-catheterization .60 years; CAD-index#23, no
history of cardiovascular disease, and no clinically significant
CAD. Dyslipidemia was defined as a previous diagnosis and/or
treatment of hypercholesterolemia (yes/no), confirmed by review
of medical records. We also constructed a third case-control group
comprising GENECARD probands included in the original
linkage scan from United States sites (N=221) and CATHGEN
controls. Institutional Review Boards approved all study protocols.
Informed consent was obtained.
Genotyping and Plasma NPY Levels
Tagged NPY SNPs were identified using the SNPSelector
program, which employs a linkage disequilibrium (LD) tagging
algorithm that prioritizes functional SNPs [37], and were then
genotyped using either Taqman or Illumina BeadArray (www.
illumina.com). The 7900HT Taqman SNP genotyping system
incorporates a standard PCR-based, dual fluor, allelic discrimina-
tion assay with a dual laser scanner. Assays were purchased through
Applied Biosystems (www.appliedbiosystems.com). QC samples,
composed of 12 reference controls, were included in each quadrant
of the plate. Illumina BeadStation genotyping was performed using
the 500G system. All SNPs examined were successfully genotyped
for $95% of the individuals in the study. Error rate estimates for
SNPs meeting QC benchmarks were ,0.2%.
Plasma NPY levels were measured by an NPY-specific
radioimmunoassay (Alpco Diagnostics, Salem NH) on 220
CATHGEN subjects, randomly selected (regardless of case/
control status) from all subjects included in the genotyping studies.
NPY levels were measured in fasting unextracted plasma collected
at time of cardiac catheterization (prior to administration of
supplementary anticoagulants if given), which was subsequently
frozen and stored at 280uC, and analyzed in a single RIA run.
Cross-reaction of the NPY RIA assay as reported by the company
is: human NPY 100%; human PYY ,2.0%; human pancreatic
polypeptide (PP) ,1.0%; NPY 1–21 ,0.1%; NPY 20–36 ,0.4%.
The assay was characterized as a mean recovery of 82% (range
75–88%) for NPY-spiked plasma. Precision was characterized by
an intra-assay CV of 2.6–3.9% in our samples, which were run in
one batch. NPY levels were approximately normally distributed.
Mouse Atherosclerosis Studies
All animal experiments complied with institutional guidelines.
Gender-matched apolipoprotein E-deficient (apoe
2/2) C57BL/6
mice were used, at the age of 1062 weeks. To accelerate
atherosclerosis, we performed endothelial denudation of the left
common carotid artery with a 0.36-mm flexible angioplasty
guidewire (Johnson and Johnson), inserted via the external carotid
arteryasdescribed[28,38].Afterligatingtheexternalcarotidartery,
we encased the common carotid in 150 ml of 22.5% (w/v) Pluronic
gel, containing either 1% (v/v) water that lacked (control) or
contained the NPY1receptor antagonist BIBP 3226 [27] (21 mmol/
L, [final]; Sigma-RBI, Inc.). The skin was closed after the Pluronic
gelled (virtually instantaneously). Postoperatively, mice were fed a
Western diet (Harlan Teklad #88137) ad libitum for two-six weeks
(until arterial harvest), and there were no differences in weight
between mice treated with vehicle or BIBP 3226. BIBP 3226 does
not affect blood pressure in rodents [26]. As we previously described
[39], arteries were perfusion/fixed and embedded in paraffin, or
embedded in OCT and frozen. Five-mm sections were stained with
a modified connective tissue stain (paraffin sections), Sudan IV
(frozen sections, for cholesteryl ester), or immunostained (frozen
sections) as previously described [38,39]: for macrophages (FITC-
conjugated rat IgG1k anti-mouse Mac3 or negative control FITC-
conjugated rat IgG1k (Pharmingen, Inc.)); smooth muscle cells
(SMCs) (Cy3-conjugated 1A4 IgG targeting SMC a-actin (Sigma));
for apoptotic cells (monoclonal rabbit IgG targeting cleaved
(activated) caspase-3 (Cell Signaling, Inc.)); or for proliferating cell
nuclear antigen (Santa Cruz Biotechnology, Inc). All sections were
digitally photographed with fixed light settings for all immunoflu-
orescence specimens within a single staining batch, to facilitate
quantitation [39]. Atherosclerosis, cellular (or protein antigen)
prevalence, and PCNA-positive nuclear prevalence [38] were
quantified with Scion Image (www.scioncorp.com) or by manual
counting by an observer blinded to specimen identity [39], from
three cross sections obtained from the distal, middle, and proximal
portions of each specimen, as described [39]. Data from these
locations were averaged for each carotid specimen.
Statistical Analysis
Ordered subset analysis (OSA) examines the impact of
covariates by defining homogeneous subsets of families for linkage
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diseases [41–44]. Similar methods were used to identify the
BRCA1 breast cancer susceptibility gene, where evidence for
linkage was only present in earlier-onset families [22,45]. Subsets
of families with earlier ages-of-onset may help evaluate genetic
heterogeneity and define subgroups with a stronger genetic effect.
A priori specification of the age-of-onset threshold is unnecessary, as
OSA uses maximal linkage evidence to define subsets. OSA was
conducted using nonparametric multipoint family-specific LODs
from microsatellite genotypes from the original screen as input [7],
with age-of-onset as a covariate. A permutation procedure
provides empirical p-values for the significance of the increase in
the maximum-subset-LOD from the overall LOD. To assess SNP
linkage, two-point LODs were calculated using Merlin [46]. The
Pedigree Disequilibrium Test (PDT) and Genotype-PDT were
used for family-based association. PDT, an extension of the
transmission-disequilibrium-test (TDT), allows incorporation of
extended pedigrees and is valid even with population substructure
[47]. Power calculations (QUANTO:http://hydra.usc.edu/)
showed power $0.80 to detect effect sizes of $2.45 for the lowest
allele frequency SNP (0.02, rs16139), and effect sizes $1.35 for the
highest allele frequency SNP (0.49, rs16147).
In CATHGEN, association was assessed using logistic regres-
sion models adjusting for race and sex; and for race, sex,
hypertension, diabetes, dyslipidemia, smoking and body-mass-
index (BMI) (multivariable model). Measured genotype analysis
using generalized linear models was performed to compare
differences in means of quantitative traits (NPY levels, age-of-
onset) by NPY genotype. Baseline differences were assessed using a
chi-square or t-test. The Graphical Overview of Linkage
Disequilibrium (GOLD) program [48] was used to assess LD.
Haplotype analysis used HaploStats 1.1.0 (Mayo Clinic, Roche-
ster, MN). We report p-values uncorrected for multiple compar-
isons, but also present results in the context of correction for LD
between SNPs [35]. The extent of atherosclerosis was compared
between control and NPY1 receptor antagonist groups in mice
with one-way ANOVA and Tukey’s post-hoc test for multiple
comparisons. SAS 9.1 (SAS Institute, Cary, NC) was used for
statistical analysis.
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